Table 3.

Ongoing clinical trials of therapeutic vaccines in NSCLC

VaccinePhaseDesign and descriptionStudy populationPrimary endpointEnrollmentNCT
L-BLP25IIIL-BLP25 + BSC vs. placebo for patients with stable disease or objective response after chemoradiotherapyUnresectable NSCLC in Asian populationOS500NCT01015443
IIIL-BLP25 vs. placebo for patients with stable disease or objective response after chemoradiotherapyUnresectable stage III NSCLCOS1,002NCT02049151
IIBLP25 and bevacizumab after definitive chemoradiotherapyNewly diagnosed stage IIIA/IIIB unresectable NSCLCSafety55NCT00828009
TG4010II/IIIEfficacy and safety of first-line therapy with or without TG4010Stage IV NSCLCPhase II: PFSPhase III: OS1,000NCT01383148

Abbreviation: BSC, best supportive care.